United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI
20 avr. 2023 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023
23 mars 2023 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
21 févr. 2023 07h00 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023
18 janv. 2023 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Record Third Quarter 2022 Financial Results
09 nov. 2022 16h05 HE
|
Evoke Pharma, Inc.
80% increase in GIMOTI® net revenue over Q2 202256% increase of GIMOTI prescription fills in Q3 compared to Q213% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 ...
Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
20 sept. 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
14 sept. 2022 08h30 HE
|
Evoke Pharma, Inc.
GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies Vote for GIMOTI as 2022 Healio Industry Breakthrough Product via Survey ...
Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution
16 août 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI)...
Evoke Pharma Reports Second Quarter 2022 Financial Results
10 août 2022 16h05 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...